Search Results 431-440 of 18368 for alopecia

1. A Study to Assess the Safety and Dose Escalation of Pegtomarginase (PT01) for Subjects with Advanced Malignancies - Mayo Clinic

   03) except for subjects with alopecia; subjects receiving luteinizing hormone-releasing hormone agonists may be considered for enrollment after discussion with ...

2. PKCι & mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer - Mayo Clinic

   Recovered from the toxic effects of radiation treatment before study entry, except for alopecia. Absolute neutrophil count (ANC) ≥ 1500 uL; Platelets (PLT) ...

3. A Safety to Evaluate the Safety and Effectiveness of Pressurized Intraperitoneal Aerosolized Chemotherapy in Ovarian, Uterine, Colorectal, and Gastric Cancer Patients - Mayo Clinic

   Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1),with the exception of alopecia, ...

4. A Study of Mogamulizumab Combined with Nivolumab in Patients who have Locally Advanced or Metastatic Solid Tumors - Mayo Clinic

   Subject with vitiligo, alopecia, type I diabetes mellitus, and endocrine deficiencies including hypothyroidism managed with replacement hormones including ...

5. Belantamab, Lenalidomide, and Daratumumab for Newly-diagnosed Multiple Myeloma - Mayo Clinic

   ... alopecia. Exclusion Criteria: Ability to understand the study procedures and provide written informed consent. Negative hepatitis B test (defined by a ...

6. A Study to Evaluate the Effectiveness of M7824 Monotherapy in Locally Advanced or Metastatic Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) - Mayo Clinic

   0 toxicity (except alopecia and vitiligo) related to prior therapy; however, sensory neuropathy Grade ≤ 2 is acceptable. Clinically significant ...

7. A Study of ABBV-085, an Antibody Drug Conjugate, for Patients with Advanced Solid Cancer Tumors - Mayo Clinic

   Unresolved adverse events ≥ Grade 2 from prior anticancer therapy, except for alopecia; Has ongoing hemolysis; Major surgery within ≤ 28 days prior to the ...

8. A Study of Investigational Immunotherapy to Determine the Safety and Effectiveness of Nivolumab and Daratumumab, with or without Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Hematologic Malignancies - Mayo Clinic

   Toxicities related to prior therapy must have returned to Grade 1 or less, except for alopecia. ... alopecia) not requiring systemic treatment, or ...

9. Phase Ib Study of Axatilimab in Combination with Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer - Mayo Clinic

   ... alopecia, are excluded. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to axatilimab or olaparib ...

10. Clinical trials - Oncology (Medical)

    Natural History Evaluation Among Female Breast Cancer Survivors with Endocrine Therapy-Induced Alopecia. Rochester, Minn., Mankato, Minn., Albert Lea, Minn ...